Beksac, M., Quach, H., Hungria, V., Pour, L., Kim, K., Voloshin, S., Sia, H., Gonzalez, E., Min, C., Lacerda, M. P. D., Sureda, A., Špička, I., Hus, M., Zherebtsova, V., Polinkovsky, M., Varghese, S., Lee, J., Manasanch, E., Robak, P., Dimopoulos, M. A. (2025). Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7544